Emmanuel J Favaloro/LinkedIn
Aug 21, 2025, 14:55
Emmanuel Favaloro on DOACs Versus Warfarin in the COVID19 Era
“Did the COVID19 pandemic push the use of DOACs to the lead in the ‘anticoagulant race’, and ahead of warfarin?
Well, yes and no.
Depends on where you live. Check out this Commentary in Seminars in Thrombosis and Hemostasis.
Just released online.
Enjoy!”

Stay informed with Hemostasis Today.
-
Sep 14, 2026, 11:16Zahra Ghasemi: Breaking the Freezer Barrier in Plasma Transfusion
-
Sep 14, 2026, 09:44Mohammad Salar Amoli: Thrombin The Master Regulator of Coagulation
-
Sep 14, 2026, 09:23Claire Harrison: HemaSphere Introduces New Patient Editor Role
-
Sep 14, 2026, 09:13Eirini Zorba: Plasmapheresis in Focus Understanding Its Role in Patient Care
-
Sep 14, 2026, 08:55Abdulrahman Al-Mashdali։ Immune Checkpoint Inhibitor Associated HLH
-
Sep 14, 2026, 07:54Islam Sadek: SOHO2026 Highlights Advances in Hematologic Malignancies
-
Sep 14, 2026, 07:45Flora Peyvandi: Building a More Equitable Future for Hemophilia Care
-
Sep 14, 2026, 07:37Joseph Pierre Aboumsallem: ET Treatment Enters a New Chapter
-
Sep 14, 2026, 07:29Eric Topol – Will AI Replace Clinicians?